ATRC241220P35000
- 4.60
- 0.000.00%
AtriCure Newsroom
Pain Management Devices Global Analysis Report 2024-2034 Featuring Abbott Laboratories, Boston Scientific, Medtronic, Nevro, Baxter, OMRON, Stryker, Teleflex, ICU Medical, AtriCure, and Zynex
AtriCure Coverage Assumed by JP Morgan at Overweight
J.P. Morgan Maintains AtriCure(ATRC.US) With Buy Rating, Maintains Target Price $40
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC) and Mettler-Toledo (MTD)
Cracking The Code: Understanding Analyst Reviews For AtriCure
AtriCure Is Maintained at Buy by Canaccord Genuity
CCORF Maintains AtriCure(ATRC.US) With Buy Rating, Raises Target Price to $61
Express News | AtriCure Inc : Canaccord Genuity Raises Target Price to $61 From $53
Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?
Baiyang Medical (301015.SZ): Currently has established a presence in the high-end medical instrument field with Atricure's atrial fibrillation treatment devices, and products like the full magnetic suspension artificial heart from Tongxin Medical.
HealthTimes reported on November 28th that Baiyang Pharmaceuticals (301015.SZ) stated in a recent investor relations event that the company has currently laid out Atricure's atrial fibrillation treatment equipment, Syncardia's fully magnetically levitated artificial heart, Medisense's ultrasound-guided electromagnetic positioning puncture device, and Wecare's home ECG monitor in the high-end medical instruments field; recently, the company has obtained the exclusive commercial operation rights of ZAP Surgical's ZAP-X Mars Rover radiotherapy surgical robot in mainland China and Hong Kong-Macao region.
AtriCure to Participate in the Piper Sandler 36th Annual Healthcare Conference
The Market Lifts AtriCure, Inc. (NASDAQ:ATRC) Shares 28% But It Can Do More
US$42.67 - That's What Analysts Think AtriCure, Inc. (NASDAQ:ATRC) Is Worth After These Results
Are Investors Undervaluing AtriCure, Inc. (NASDAQ:ATRC) By 29%?
AtriCure | 10-Q: Q3 2024 Earnings Report
AtriCure Is Maintained at Overweight by JP Morgan
Snap Posts Upbeat Earnings, Joins Unisys, AtriCure, Garmin And Other Big Stocks Moving Higher On Wednesday
AtriCure Up Over 23%, on Pace for Largest Percent Increase Since June 2009 -- Data Talk
Q3 2024 AtriCure Inc Earnings Call
AtriCure Plans a Surgical Pulsed Field Ablation Play